Open AccessLumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR
Author(s) -
Steven M. Rowe,
Susanna A. McColley,
Ernst Rietschel,
Xiaolei Li,
Scott C. Bell,
Michael W. Konstan,
Gautham Marigowda,
David A. Waltz,
Michael Boyle
Publication year - 2017
Publication title -
annals of the american thoracic society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 114
eISSN - 2329-6933
pISSN - 2325-6621
DOI - 10.1513/annalsats.201609-689oc
Subject(s) - ivacaftor , medicine , cystic fibrosis , placebo , regimen , randomized controlled trial , gastroenterology , cystic fibrosis transmembrane conductance regulator , pathology , alternative medicine
In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function.